Dental Pain-Pipeline Review, H2 2017

Dental Pain-Pipeline Review, H2 2017


  • Products Id :- GMDHC9965IDB
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dental Pain-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain-Pipeline Review, H2 2017, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.

A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dental Pain-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dental Pain-Overview

Dental Pain-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Dental Pain-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dental Pain-Companies Involved in Therapeutics Development

Laboratorios Del Dr Esteve SA

Pacira Pharmaceuticals Inc

Teva Pharmaceutical Industries Ltd

Dental Pain-Drug Profiles

(celecoxib + tramadol hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AFAP-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bupivacaine ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

funapide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dental Pain-Dormant Projects

Dental Pain-Discontinued Products

Dental Pain-Product Development Milestones

Featured News & Press Releases

Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac

Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Dental Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Dental Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dental Pain-Pipeline by Laboratorios Del Dr Esteve SA, H2 2017

Dental Pain-Pipeline by Pacira Pharmaceuticals Inc, H2 2017

Dental Pain-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Dental Pain-Dormant Projects, H2 2017

Dental Pain-Dormant Projects, H2 2017 (Contd..1), H2 2017

Dental Pain-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Laboratorios Del Dr Esteve SA

Pacira Pharmaceuticals Inc

Teva Pharmaceutical Industries Ltd

select a license
Single User License
USD 2000 INR 138340
Site License
USD 4000 INR 276680
Corporate User License
USD 6000 INR 415020

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com